Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin DDI with Progestins and Midazolam in Healthy Women
NCT03353857Phase 1Completed
- Sponsor
- Bayer
- Start
- Nov 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of levonorgestrel intrauterine system, norethindrone, desogestrel, dienogest, drospirenone and 1 more in contraception and endometriosis, sponsored by Bayer. Primary endpoints: Area under the plasma concentration time curve from zero to infinity and Maximum plasma concentration. Started Nov 2017; status: completed.
02
Drugs
levonorgestrel intrauterine systemnorethindronedesogestreldienogestdrospirenone
03
Conditions
contraceptionendometriosis
Beyond the preview
Go deeper on NCT03353857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03353857.